Neuland Laboratories

Neuland Laboratories ROE

The Return on Equity (ROE) of Neuland Laboratories (NEULANDLAB.NS) as of Oct 31, 2026 is 19.42 %. In the previous year, Return on Equity (ROE) was 17.06 % — a change of 13.84% (higher).

ROE

19.42 %

YoY

13.84%

Last updated:

In 2026, Neuland Laboratories's return on equity (ROE) was 19.42 %, a 13.84% increase from the 17.06 % ROE in the previous year.

The Neuland Laboratories ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2019
2.35 INR
Jan 1, 2020
2.28 INR
Jan 1, 2021
10.25 INR
Jan 1, 2022
7.59 INR
Jan 1, 2023
16.45 INR
Jan 1, 2024
23.39 INR
Jan 1, 2025
17.06 INR
Jan 1, 2026
19.42 INR
The Neuland Laboratories ROE history
YEARROEYoY
19.42 %+13.84%
17.06 %-27.08%
23.39 %+42.22%
16.45 %+116.62%
7.59 %-25.94%
10.25 %+349.02%
2.28 %-2.88%
2.35 %+8.77%
2.16 %-74.83%
8.59 %-41.33%
14.64 %+48.16%
9.88 %-54.30%
21.62 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Neuland Laboratories Stock analysis

What does Neuland Laboratories do? Neuland Laboratories Ltd. generates revenue through the manufacture and export of bulk pharmaceutical ingredients and intermediates for the generics industry. The company operates in a single segment focused on active pharmaceutical ingredients (APIs) and allied services, with two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, and Labetalol, which are supplied to both domestic and international markets. The firm provides end-to-end chemistry solutions for the pharmaceutical industry, covering synthesis of library compounds, NCEs, and advanced intermediates across clinical and commercial stages. The company's primary customers are pharmaceutical firms requiring APIs and intermediates for generic drugs, with a focus on global markets. Neuland Laboratories Ltd. serves as a solution provider for chemistry needs, offering services from early-stage development to commercial production. The business model emphasizes tailored manufacturing services under CMS, alongside standardized GDS products, catering to the full lifecycle of pharmaceutical development and production. Revenue streams are derived from the sale of specific APIs like Levetiracetam and Mirtazapine, as well as custom manufacturing services for complex chemical processes. The firm's dual verticals allow it to address diverse market demands, with GDS targeting cost-effective generic drug production and CMS focusing on specialized, high-value manufacturing solutions for pharmaceutical clients. Neuland Laboratories is one of the most popular companies on Eulerpool.

ROE Details

Decoding Neuland Laboratories's Return on Equity (ROE)

Neuland Laboratories's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Neuland Laboratories's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Neuland Laboratories's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Neuland Laboratories’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Neuland Laboratories stock

Return on Equity (ROE) of Neuland Laboratories is 19.42 % in 2026.

Return on Equity (ROE) of Neuland Laboratories changed from 17.06 % to 19.42 %, representing a 13.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Neuland Laboratories since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Neuland Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Neuland Laboratories

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Neuland Laboratories